Press Release May 14 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report for its Ambernath API manufacturing facility. The inspection by the USFDA took place in February and concluded with no observations, classifying the facility as No Action Indicated. This disclosure is made in accordance with regulatory requirements for transparency to investors and exchange members.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 08 2025
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
- Press Release Apr 30 2025
- Press Release Apr 26 2025
- Press Release Apr 25 2025
Later from Zydus Lifesciences
- Press Release May 20 2025
- Press Release May 23 2025
- Press Release May 28 2025
- Zydus Lifesciences Limited Press Release Jun 02 2025
- Press Release Jun 10 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences